Moleculin Biotech (MBRX) Times Interest Earned (2016 - 2026)
Moleculin Biotech (MBRX) posted quarterly Times Interest Earned of -$183.73 for Q4 2025, down 7.87% year-over-year from -$199.42 in Q4 2024, and down 24.44% quarter-over-quarter from -$147.65 in Q3 2025.
Moleculin Biotech (MBRX) Times Interest Earned (2016 - 2026) Analysis & Trends
Moleculin Biotech's Times Interest Earned history runs 10 years deep, the most recent figure standing at -$183.73 for Q4 2025.
- In Q4 2025, Times Interest Earned fell 7.87% year-over-year to -$183.73; the TTM figure through Dec 2025 stood at -$157.87 (up 14.07% YoY), while the FY2025 annual figure was -$0.57, up 16.77% from the prior year.
- Times Interest Earned for Q4 2025 stood at -$183.73, down from -$147.65 in the prior quarter.
- The five-year high for Times Interest Earned was -$146.67 in Q2 2025, with the low at -$432.57 in Q3 2022.
- The 5-year median for Times Interest Earned is -$177.49 (2021), against an average of -$199.77.
- The sharpest annual moves came in 2021 and 2023: Times Interest Earned sank 525.51% in 2021, then jumped 59.56% in 2023.
- Moleculin Biotech's Times Interest Earned stood at -$148.71 in 2021, then slipped by 24.72% to -$185.47 in 2022, then tumbled by 92.35% to -$356.76 in 2023, then jumped by 52.26% to -$170.33 in 2024, then retreated by 7.87% to -$183.73 in 2025.
- Business Quant data shows MBRX's Times Interest Earned at -$183.73 in Q4 2025, -$147.65 in Q3 2025, and -$146.67 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.42 |
| 10 | Moleculin Biotech | 3.37 Mn | 3.37 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -184.41 |
| Dec 31, 2025 | -183.73 |
| Sep 30, 2025 | -147.65 |
| Jun 30, 2025 | -146.67 |
| Mar 31, 2025 | -152.38 |
| Dec 31, 2024 | -170.33 |
| Sep 30, 2024 | -182.95 |
| Jun 30, 2024 | -162.76 |
| Mar 31, 2024 | -230.24 |
| Dec 31, 2023 | -356.76 |
| Sep 30, 2023 | -174.91 |
| Jun 30, 2023 | -168.71 |
| Mar 31, 2023 | -219.84 |
| Dec 31, 2022 | -185.47 |
| Sep 30, 2022 | -432.57 |
| Jun 30, 2022 | -212.40 |
| Mar 31, 2022 | -202.11 |
| Dec 31, 2021 | -148.71 |
| Sep 30, 2021 | -175.91 |
| Jun 30, 2021 | -162.26 |